BIO: Dr. Kenneth J. Hillan, M.B., Ch.B., has been the President of R&D at Achaogen, Inc. since January 1, 2018. Dr. Hillan served as the Chief Executive Officer at Achaogen, Inc. from October 3, 2011 to December 31, 2017 and served as its President. Dr. Hillan also manages the Pathology department and its ongoing work in oncology, immunology, vascular biology and other therapeutic areas. He served as Chief Medical Officer of Achaogen, Inc. since March 2011 until July 14, 2014 and served as its President since October 3, 2011. He served as Senior Vice President of Product Development and Head of Clinical Development of Inflammation DBA at Genentech, Inc. He served as a Vice President of Immunology, Tissue Growth and Repair at Genentech, Inc. He served as a Senior Vice President of Clinical Development, Inflammation at Genentech and its Vice President of Research Operations and Pathology; Vice President of Development Sciences; and Vice President of Immunology, Tissue Growth and Repair (ITGR). He served a Vice President of Research Operations and Pathology of Genentech and was responsible for operational management of Genentech's Research organization, ensuring consistent implementation of strategic objectives and improvements in Research productivity. He was into Genentech in 1994 to study the role of hepatocyte growth factor in liver regeneration. He worked at Genentech from August 1994 to April 2011. He also served as Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. He joined the Pathology department as a Scientist in 1996 and served as a Director of Pathology since 1998. He served as a Senior Director of Research Operations of Genentech since 2001. He also is an Honorary Professor of Molecular and Therapeutic Pathology at the University of Leeds. He has been a Director of Zymeworks Inc. since February 3, 2017. He has been a Director of Achaogen, Inc., since October 3, 2011. He served as Director of Relypsa, Inc. since June 19, 2014 to September 2016. He is on the Editorial Advisory Board of the Journal of Pathology and is an ad hoc reviewer for the Journal of Clinical Pathology and the American Journal of Pathology and Liver. He has published more than 40 articles in peer-reviewed journals. He has also authored dozens of scientific publications and is a named inventor on almost 50 issued patents. He holds M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow University in Scotland in 1983. He was named a Fellow of the Royal College of Surgeons (FRCS) in 1989 and was Named a Member of the Royal College of Pathologists (MRCPath) in 1993.

Michel Vounatsos

CEO of Biogen

BIO: Mr. Michel Vounatsos has been the Chief Executive Officer of Biogen Inc. since January 6, 2017. Mr. Vounatsos served as the Chief Commercial Officer and Executive Vice President of Biogen Inc. since April 18, 2016 until December 2016. He is a sophisticated global business leader who has a track record of commercial success and creativity. He joined Biogen after a 20 year career at Merck, where he various positions including served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. He has been Director of Biogen Inc. since January 6, 2017. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.